Liquid biopsies in lung cancer: The new ambrosia of researchers

Rolfo, Christian; Castiglia, Marta; Hong, David S.; Alessandro, Riccardo; Mertens, Inge; Baggerman, Geert; Zwaenepoel, Karen; Gil-Bazo, Ignacio; Passiglia, Francesco; Carreca, Anna Paola; Taverna, Simona; Vento, Renza; Peeters, Marc; Russo, Antonio; Pauwels, Patrick

doi:10.1016/j.bbcan.2014.10.001

Cited by 134 publications

(129 citation statements)

References 78 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…Under circumstances when re-biopsy is not feasible, comprehensive genomic detection and multi-targeted therapies may be used. It has been suggested that liquid biopsy may reveal relatively comprehensive gene alternations and provide predictive information on the identification of therapeutic targets and resistance mechanisms (35).…”

Section: Discussionmentioning

confidence: 99%

EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature

Yang

Zhang

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered to be effective treatments for advanced non-small cell lung cancer (NSCLC) patients with sensitizing EGFR mutations, including exon 19 deletion and exon 21 L858R mutations. However, with the development of EGFR mutation detection assays, patients with complex EGFR mutations are emerging, and their response to EGFR-TKIs remains unclear. The present study reports a case of a 62-year-old, non-smoking female patient with advanced NSCLC, presenting with concurrent EGFR 19+21 sensitizing mutations, who had a poor response to the first-line EGFR-TKI erlotinib and succumbed 5 months subsequent to diagnosis. Furthermore, the present study performed a literature review, and 18 patients with complex EGFR 19+21 mutations that had received EGFR-TKIs were identified. The majority of these patients responded well to EGFR-TKIs. To the best of our knowledge, the present case is the first to report a patient with lung adenocarcinoma with complex EGFR 19+21 sensitizing mutations that had a poor clinical response to a first-line EGFR-TKI. Despite the 70% response rate of sensitizing EGFR-mutant NSCLCs to EGFR-TKIs, there is still a proportion of patients that experience de novo resistance, and heterogeneity is likely to be important in this resistance mechanism. Therefore, comprehensive genomic detection assays and multi-targeted therapies for patients with NSCLC with complex EGFR mutations require additional investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature

Yang

Zhang

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Most of the CTCs populations analyzed exhibit heterogeneity, pointing to release of different cell populations from distinct regions of the tumor or from metastatic lesions. Out of all CTCs shed by the primary tumor only about 0.1% survives in the circulation and less than 0.01% is capable of forming secondary lesions (57,68,69). This attrition has been attributed to shear stress and an unfavorable microenvironmental conditions in the blood.…”

Section: Sclc and Ctcsmentioning

confidence: 99%

“…CTCs are rare events in most tumor types, with a frequency of approximately one CTC among 1-10 million mononuclear blood cells (4,57). Therefore, these cancer cells have to be enriched by various methods for further analysis.…”

Section: Sclc and Ctcsmentioning

confidence: 99%

Circulating tumor cell interactions with macrophages: implications for biology and treatment

Hamilton¹,

Rath²

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

CTCs. SCLC has an unfavorable prognosis due to rapid dissemination and early chemoresistant relapses. SCLC CTCs recruit macrophages and elicit secretion of various cytokines and the six CTC lines expresschitinase-3-like-1 (CHI3L1), vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP9) in abundance. CHI3L1 is cytokine/growth factor expressed in inflammation and cancer and found to be correlated to metastasis and a dismal prognosis. In conclusion, SCLC CTCs have acquired the essential means for aggressiveness and invasion in a tumor microenvironment specifically shaped by macrophages and inflammation.

show abstract

“…The presence of CTCs has been associated with poor outcomes in advanced stage cancer patients (8)(9)(10). With the use of the CellSearch system, CTC number was a strong predictor of overall survival (OS) in a cohort of 101 patients with non-small cell lung cancer (NSCLC) (11).…”

Section: Circulating Tumor Cells (Ctcs)mentioning

confidence: 99%

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Xu‐Welliver¹,

Carbone²

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Despite recent advances, non-small cell lung cancer (NSCLC) remains a devastating disease with overall poor prognosis. Major contributing factors include obstacles to diagnosing the disease early in its course during the asymptomatic stage as well as diversity and complexity of its biology underlying tumorigenesis and tumor progression. Advances in molecularly targeted therapies which drives the development of personalized cancer care require precise and comprehensive understanding of tumor biology, not only at the time of diagnosis but also during treatment course and surveillance. As lung tumor tissue can be difficult to obtain without invasive and potentially risky procedures, it is difficult to monitor treatment response with serial tissue biopsies. Development of non-invasive but reliable blood based tumor markers has become an important research area. In this review, we focus on the following circulating biomarkers that have been identified in recent years: circulating tumor cells (CTCs); circulating cell-free nucleic acids, such as circulating tumor DNA (ctDNA) and microRNA (miR); and other biomarkers such as genomic and proteomic features. These biomarkers not only have prognostic values, but also can help guild treatment decisions by monitoring tumor burden, detecting minimal residual disease and/or recurrent disease, as well as monitoring evolution of genetic alterations throughout the treatment course.

show abstract

Liquid biopsies in lung cancer: The new ambrosia of researchers

Cited by 134 publications

References 78 publications

EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature

EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature

Circulating tumor cell interactions with macrophages: implications for biology and treatment

Blood-based biomarkers in lung cancer: prognosis and treatment decisions

Contact Info

Product

Resources

About